Fujifilm Diosynth Biotechnologies

What Fujifilm Diosynth Biotechnologies does

FUJIFILM Biotechnologies (legal entity Fujifilm Diosynth Biotechnologies) is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end biopharmaceutical process development, analytical, and cGMP manufacturing services from preclinical through commercial supply. The company serves 22-23 of the top 30 global pharmaceutical companies alongside 30-60 emerging biotech and startup clients, with major 10-year anchor agreements including Regeneron (over $3 billion) and Johnson & Johnson ($2 billion) for biologics manufacturing at its Holly Springs, North Carolina campus.

The company operates a vertically integrated technology stack anchored by proprietary platforms: ApolloX (CHO cell line development delivering DNA-to-RCB in 10 weeks with mAb titers up to 10 g/L), MaruX (continuous mammalian manufacturing), Paveway PLUS (antibiotic-free microbial expression), ShunzymeX (scarless protease purification developed with the University of Edinburgh), SymphonX (automated downstream processing), and the kojoX global production network spanning nine facilities across the United States, United Kingdom, Denmark, and Japan. Manufacturing modalities include mammalian cell culture (20,000L stainless steel and 2,000L/5,000L single-use bioreactors), microbial fermentation, insect cell/baculovirus systems, viral vector gene therapy (AAV, LV, AdV, HSV, retrovirus), cell therapy (autologous/allogeneic including iPSC, MSC, CAR-T, NK, TCR-T), and aseptic fill-finish.

Revenue is generated through bespoke long-term manufacturing agreements, project-based development contracts, and exclusive capacity reservations negotiated via direct enterprise field sales. Pricing is quote-based and not publicly disclosed. The company is a wholly-owned subsidiary of Fujifilm Holdings Corporation, financed through parent resources and customer commitments, with cumulative capital investment exceeding $3.2 billion at Holly Springs and £400 million at its Teesside, UK site. The firm is in active commercial expansion, evidenced by the September 2025 Holly Springs operational launch (800+ employees), the February 2026 Teesside inauguration as the UK's largest single-use CDMO facility, and selection for the FDA PreCheck Pilot Program.

Name

Fujifilm Diosynth Biotechnologies

Legal name

FUJIFILM Biotechnologies

Website

https://fujifilmbiotechnologies.fujifilm.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

FUJIFILM Biotechnologies is a global CDMO providing end-to-end biopharmaceutical development and manufacturing across mammalian, microbial, gene therapy, and cell therapy modalities to 22-23 of the top 30 global pharma companies and 30-60 emerging biotech firms.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biopharmaceutical CDMO services
• Contract development manufacturing
• Mammalian cell culture
• Gene therapy manufacturing
• Cell line development

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain

Revenue model

1. Contract Development and Manufacturing Organization (CDMO) Services: FUJIFILM Biotechnologies operates as a CDMO providing process development through commercial manufacturing of biopharmaceuticals. Revenue is generated through long-term manufacturing agreements, project-based service contracts, and capacity reservations with pharmaceutical and biotech companies. Major deals include a 10-year $3B+ agreement with Regeneron and a 10-year $2B agreement with Johnson & Johnson for manufacturing space at the Holly Springs, NC facility.
2. Technology Development and Licensing: Revenue generated through development of proprietary technology platforms (ShunzymeX, ApolloX, Paveway PLUS) created in collaboration with partners such as the University of Edinburgh, with potential for technology licensing as platforms mature.
3. cGMP Manufacturing Services: cGMP manufacturing of drug substance and drug product across mammalian, microbial, insect cell, gene therapy, and cell therapy modalities. Includes analytical and quality services, CMC services, fill-finish, and finished goods assembly, labeling, and packaging.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

FUJIFILM Diosynth Biotechnologies is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end biopharmaceutical process development, analytical, and cGMP manufacturing services from preclinical through clinical and commercial supply. Services span mammalian cell culture, microbial fermentation, insect cell culture (baculovirus expression), gene therapy (AAV, AdV, LV, HSV, Retrovirus vectors), and cell therapy (autologous and allogeneic, including iPSC, MSC, CAR-T, NK, TCR-T), including drug substance manufacturing, drug product fill-finish, and CMC services.

Product overview

FUJIFILM Biotechnologies is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end biopharmaceutical manufacturing services from process development through commercial supply. The company operates as an integrated platform offering mammalian cell culture services (via ApolloX™ cell line development platform and MaruX™ continuous manufacturing), microbial fermentation (via Paveway™ PLUS expression platform), advanced therapies including gene therapy and cell therapy manufacturing, and comprehensive CMC services. Key technology platforms include ShunzymeX™ for precision purification and SymphonX™ for downstream purification. The global production network is coordinated through the kojoX™ platform enabling standardized operations across facilities in the US, UK, Denmark, and Japan. Services span drug substance manufacturing (with Scale Up/Scale Out/Scale On strategies), drug product fill-finish, and analytical quality services supporting IND/IMPD and BLA/MAA regulatory filings.

Differentiator

Problem solved

Functional benefit

Products and services

• Mammalian Cell Culture CDMO Services Complete solutions for cell line and process development, late phase activities, clinical and commercial cGMP manufacturing of biopharmaceuticals including monoclonal antibodies, non-mAbs, fusion proteins, and multispecifics. Supported by the ApolloX cell line development platform and MaruX continuous manufacturing platform.
• Microbial Fermentation CDMO Services Microbial CDMO solutions for strain selection, process development, and commercialization across E. coli, P. pastoris, and S. cerevisiae hosts, including difficult-to-express proteins, potent APIs, and PEGylation/conjugation chemistries. Supported by the Paveway PLUS expression platform.
• Insect Cell Culture / Baculovirus Expression System CDMO Services Comprehensive workflows for developing, scaling, and manufacturing using insect cell culture and baculovirus expression vector systems (BEVS), with line of sight to commercialization for vaccines and virus-like particles.
• Gene Therapy CDMO Manufacturing End-to-end viral gene therapy manufacturing including AAV, AdV, LV, HSV, and Retrovirus vectors for gene therapies and oncolytic viruses. Offers upstream/downstream development, candidate screening, feasibility studies, platform processing, and cGMP production.
• Cell Therapy CDMO Services Full end-to-end cell therapy services including stem cells (MSCs, HSCs, iPSCs), immune cells (CTLs, NK cells, CAR-T, TCR-T), both autologous and allogeneic solutions, from preclinical through commercial manufacturing.
• Drug Substance CDMO Manufacturing cGMP mammalian drug substance manufacturing with three major strategies: Scale Up (20,000L bioreactors), Scale Out (2,000L single-use bioreactors), and Scale On/Continuous (500L bioreactors).
• Drug Product CDMO Services Aseptic filling solutions with flexibility of formats for vials, pre-filled syringes, and cartridges. Includes gloved and gloveless robotic isolators, visual inspection, formulation development, and stability testing.
• Fill-Finish CDMO Manufacturing cGMP pharmaceutical fill-finish manufacturing including assembly services for pre-filled syringes and auto-injectors (via SHL Medical partnership), labeling, and packaging services, with over 16 years of experience delivering therapies to over 65 countries.
• Analytical and Quality Services Comprehensive analytical solutions including method development, transfer, validation, quality control testing, physiochemical and biochemical characterization, and biosafety testing for IND/IMPD or BLA/MAA filings.
• CMC Services Comprehensive Chemistry, Manufacturing and Controls services including cell banking, formulation development, structure elucidation, comparability studies, method validation, stability studies, process characterization, process validation, and regulatory support.
• Vaccine Production CDMO Services Vaccine development from pre-clinical to commercial supply across mammalian, microbial, and insect cell culture for viral/bacterial and non-viral vaccines, leveraging over 30 years of microbial and virus-based cGMP biomanufacturing experience.
• ShunzymeX Precision Purification Technology A precision purification technology for complex biologics that simplifies and streamlines downstream processing using a novel scarless protease, reducing three purification steps to one and creating a faster path to GMP. Developed in collaboration with the University of Edinburgh.

Quantifiable outcome

• From DNA to Research Cell Bank in as little as 10 weeks using ApolloX platform
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered flagship and core.

• Johnson & JohnsonflagshipStrategic or Co-development Partner · 28 August 2025$2 billion commitment over 10 years for exclusive use of manufacturing space at Fujifilm's Holly Springs, NC facility for production of monoclonal antibodies and other biologics. Part of J&J's broader $55 billion U.S. investment scheme. The Holly Springs site will employ approximately 725 workers across 160,000 square feet.
• FDA (PreCheck Pilot Program)coreOthers · 29 June 2025Selected as one of seven pharmaceutical companies for the FDA PreCheck Pilot Program designed to accelerate regulatory reviews of new domestic manufacturing facilities. Regulators review facilities while under construction to catch and correct issues early, potentially saving up to 14 months in approval process. Aligns with U.S. domestic drug production priorities.
• Regeneron PharmaceuticalsflagshipStrategic or Co-development Partner · 22 April 202510-year manufacturing agreement for bulk drug product of Regeneron's commercial biologic medicines at Fujifilm's Holly Springs, North Carolina campus. Total investment estimated to exceed $3 billion, nearly doubling Regeneron's U.S. large-scale manufacturing capacity. Complements Regeneron's ~$3.6 billion expansion of its Tarrytown, NY campus, with total planned investments in NY and NC exceeding $7 billion.
• SHL MedicalcoreStrategic or Co-development Partner · 8 January 2024Strategic partnership announced January 2024 for autoinjector assembly, labeling, and packaging services. SHL Medical's Molly autoinjector platform expands FUJIFILM Biotechnologies' finished goods capabilities for pharmaceutical and biotech companies offering self-injection device medicines. Collaboration aims to streamline processes and enhance efficiency.
• RoosterBiocoreStrategic or Co-development Partner · 14 July 2023Collaboration to enable cGMP manufacturing of Mesenchymal Stem Cell (MSC) and Exosome (Extracellular Vesicle) therapies. RoosterBio provides process and analytical development for MSCs and exosomes, followed by seamless tech transfer to FUJIFILM Biotechnologies' cGMP manufacturing network. Partnership accelerates path to clinical and commercial for MSC-based therapies.
• University of EdinburghcoreStrategic or Co-development Partner · 1 January 2019Strategic partnership began in 2019 with joint funding from UK Research and Innovation (UKRI). Resulted in ShunzymeX precision purification technology - a novel scarless protease that simplifies microbial downstream processing for complex biologics. Partnership established the foundation for a differentiated purification platform.
• VeevacoreTechnology or IntegrationFUJIFILM Biotechnologies is cited as a case study demonstrating reduced lead times, improved audit readiness, and simplified approval workflows using Veeva Quality Cloud's external collaboration features for digital quality ecosystems. Replaces manual email-based communication with unified digital quality management.
• FUJIFILM Cellular DynamicscoreStrategic or Co-development PartnerFUJIFILM Cellular Dynamics offers contract development and cGMP manufacture of clinical-grade human induced pluripotent stem cells (iPSCs) and differentiated cells. Partnership with FUJIFILM Biotechnologies enables end-to-end iPSC-based cell therapy manufacturing from pluripotent stem cells through differentiated cell therapy production and distribution.

Scale indicators12 records

Recent moves9 records

Direct peers

• Lonza Group: Lonza is the largest pure-play biologics CDMO globally, offering mammalian cell culture, microbial fermentation, and cell & gene therapy services. It competes head-to-head with FUJIFILM Biotechnologies for large-pharma biologics contracts and serves many of the same top-30 pharma customers.
• Samsung Biologics: Samsung Biologics operates massive mammalian cell culture CDMO facilities in South Korea with similar large-scale stainless-steel bioreactor capacity to FUJIFILM Biotechnologies' Holly Springs site. It is a primary competitor for big-pharma biologics manufacturing contracts and is also expanding into advanced therapies.
• WuXi Biologics: WuXi Biologics is one of the largest biologics CDMOs globally with extensive mammalian and microbial capacity. It directly competes with FUJIFILM Biotechnologies for global pharma contracts, though its exposure to BIOSECURE legislation creates a notable differentiation opportunity for FUJIFILM in the US market.
• Catalent (Novo Holdings): Catalent provides biologics CDMO services including mammalian cell culture and fill-finish, acquired by Novo Holdings in 2024. It competes with FUJIFILM Biotechnologies across both drug substance and drug product services for large pharma accounts.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's BioXcellence is the company's global contract biopharmaceutical manufacturing business, offering mammalian cell culture, microbial, and viral vector services. It is a direct competitor particularly for viral gene therapy and complex biologics manufacturing contracts.
• Rentschler Biopharma: Rentschler Biopharma is a mid-sized European CDMO specializing in mammalian cell culture and complex proteins. FUJIFILM Biotechnologies' incoming CBO Christiane Bardroff was formerly COO at Rentschler, illustrating the direct competitive overlap for European biopharma clients.
• AGC Biologics: AGC Biologics offers mammalian, microbial, and cell & gene therapy CDMO services across facilities in the US, Europe, and Japan. It competes directly with FUJIFILM Biotechnologies particularly in gene therapy and viral vector manufacturing.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Thermo Fisher's Pharma Services division (including Patheon) offers biologics manufacturing, fill-finish, and clinical supply services alongside a much broader life sciences portfolio. It overlaps with FUJIFILM Biotechnologies on drug substance and fill-finish CDMO contracts.

Emerging players

• Recipharm: Recipharm (owned by EQT) is a European-focused CDMO providing biologics fill-finish and drug product services, with growing biologics capabilities. It competes with FUJIFILM Biotechnologies in European fill-finish and smaller-scale biologics manufacturing.

Others

• Charles River Laboratories: Charles River provides cell & gene therapy CDMO services (acquired Cognate BioServices) and biologic safety/testing services. It is an adjacent/ecosystem player rather than a direct competitor, but increasingly overlaps with FUJIFILM Biotechnologies in viral vector manufacturing and biosafety testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/fujifilmdiosyn
• LinkedInlinkedin.com/company/fujifilm-diosynth-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fujifilm Diosynth Biotechnologies